Combining PARP & Androgen Receptor Inhibitors in Prostate Cancer: New Insights into the Mechanism of Action
Time: 10:30 am
day: Day One
Details:
- Explore the interplay between PARPi and AR inhibition in preclinical prostate cancer models and the mechanism of action providing combination activity beyond HRD prostate cancer
- Review of the DNA repair role of AR and regulation by PARP1 and the induction of DNA damage and genomic instability from combination treatment
- Discuss how these insights provide a rationale for the clinical activity of PARPi plus ARi in HRR proficient mCRPC
